Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Understanding and Treating Female Sexual Dysfunction: An Update on Current Literature – Part 2

By: Sheryl A. Kingsberg, Ph.D.; James A. Simon, MD, CCD, NCMP, IF, FACOG

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1

Female sexual dysfunction (FSD) is an overall umbrella disease that may affect as many as 40 million women in the U.S., with prevalence rates cited from 30% to as high as 80%. The etiology of FSD, however, is less well-defined or understood. Comprising both physiological and psychological aspects, FSD can manifest in a variety of ways. This educational activity will include discussions on the definition, prevalence, diagnosis and related guidelines for managing this disease state.

Expiration Date: Wednesday, October 31, 2018
Release Date: October 2017

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss treatment options for women with female sexual dysfunction, including the first available medication for a specific type of female sexual dysfunction
  • Discuss the prevalence of female sexual dysfunction and counseling programs
  • Evaluate the differences in definitions, severity criteria, and duration of disease for female sexual dysfunction as published in DSM-5

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grantor Statement
This continuing medical education activity is supported through an educational grant from Valeant Pharmaceuticals North America LLC.

Faculty and Disclosures

Sheryl A. Kingsberg, Ph.D.
Chief, Division of Behavioral Medicine
Department of OB/GYN
MacDonald Women’s Hospital
University Hospitals Cleveland Medical Center
Professor, Departments of Reproductive Biology and Psychiatry
Case Western Reserve University School of Medicine
Cleveland, Ohio

James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Professor
Department of Ob/Gyn
George Washington University
Medical Director
Women’s Health & Research Consultants®
Washington, DC

 

The following faculty members have the following financial relationships with commercial interests:

Sheryl A. Kingsberg, Ph.D. has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AMAG Pharmaceuticals, Inc.; Emotional Brain; Endoceuticals Inc; Palatin Technologies; and Valeant Pharmaceuticals North America LLC. Grant/Research Support: Palatin Technologies.

Simon MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AbbVie, Inc.; Allergan, Plc; AMAG Pharmaceuticals, Inc.; Amgen Inc.; Apotex, Inc.; Ascend Therapeutics; Azure Biotech, Inc.; Eisai, Inc.; JDS Therapeutics, LLC; Merck & Co., Inc;  Millendo Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Novo Nordisk;  Nuelle, Inc.; Perrigo Company, PLC; Radius Health, Inc.;, Regeneron Pharmaceuticals, Inc.; Roivant Sciences, Inc.; Sanofi S.A.; Sebela Pharmaceuticals, Inc.; Sermonix Pharmaceuticals, Inc.; Shionogi Inc.; Sprout Pharmaceuticals; Symbiotec Pharmalab; TherapeuticsMD; and Valeant Pharmaceuticals. Grant/Research Support: AbbVie, Inc.; Actavis, PLC; Agile Therapeutics; Bayer Healthcare LLC.; GlaxoSmithKline’ New England Research Institute, Inc.; Novo Nordisk; Palatin Technologies; Symbio Research, Inc.; and TherapeuticsMD. Patent and Trademark Holder: U.S. Patent: 4,816,257, March 28, 1989: “Method for Producing an In Vivo Environment Suitable for Human Embryo Transplant.”, U.S. Trademark: Reg. No. 3,446,895, Registered June 10, 2008: “You talk…I’ll Listen. We’ll Plan Together”. U.S. Trademark: Reg. No. 3,676,269, Registered September 1, 2009: U.S. Trademark: Reg. No. 3,760,080, Registered March 16, 2010: “Women’s Health & Research Consultants & Design”, U.S. Trademark Serial No.:86-714,153. “DR. SIMON SAYS” Registered February 2, 2016. Stock Shareholder and/or other Financial Support: Sermonix Pharmaceuticals.

 

Michelle Dalton, Writer and Cheryl Cavanaugh, MS, Evolve Medical Education LLC have no real or apparent conflicts of interest to report.

Rishi P. Singh, MD, Peer Reviewer,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alcon; Allergan  Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Video Resources

Part one

Part two

BackNext